Journal ArticleOPEN ACCESS

Why the CRISPR patent verdict isn’t the end of the story

  • Ledford H
Nature (2017)
DOI: 10.1038/nature.2017.21510
N/ACitations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

From legal challenges to ongoing experimentation, the story of who owns the rights to CRISPR–Cas9 gene editing is still being written.

Cite

CITATION STYLE

APA

Ledford, H. (2017). Why the CRISPR patent verdict isn’t the end of the story. Nature. https://doi.org/10.1038/nature.2017.21510

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free